At what level of hyperkalemia or creatinine elevation should ACE inhibitor therapy be stopped or not started?

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 9, 2001, Pages 754-760

  Nurko, S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERKALEMIA; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; NOTE; POTASSIUM BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034840275     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.9.754     Document Type: Note

References (23)

1. Renal failure related to angiotensin-converting enzyme inhibitors
2. Control of glomerular filtration rate by renin-angiotensin system
3. Dissociation of renal blood flow and filtration rate autoregulation by renin depletion
4. Postmarketing surveillance of enalapril II: Investigation of the potential role of enalapril in deaths with renal failure
5. ACE inhibitors in renovascular hypertension
6. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension
7. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
8. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE)
9. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS)
10. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
11. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the studies of left ventricular dysfunction (SOLVD)
12. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure
13. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
14. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
15. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
16. Clinical pharmacology of ramipril
17. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis randomized trials
18. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial
19. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial
20. Prevention of progression in non-diabetic chronic renal failure
21. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril
22. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
23. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infraction, and stroke in high-risk patients